2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
DGAP-Ad-hoc: Merck KGaA / Key word(s): Study/Study results
Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.
While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) that have high expression of PD-L1 (the "Clinical Trial"), the Independent Data Monitoring Committee recommended on January 19, 2021 to discontinue the Clinical Trial. Based on this recommendation, the Company has made the decision to discontinue the Clinical Trial, as the study is unlikely to meet the primary efficacy endpoint. The recommendation by the Independent Data Monitoring Committee and the Company's decision is related only to this Clinical Trial. Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world. An investor and analyst call with the Company's management is scheduled for 2:00 pm (CET). Andreas Cezanne - Head of Corporate Media Relations Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany Phone: +49 151-14542702
20-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 - 6328 |
| E-mail: | Friederike.Segeberg@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 1161977 |
| End of Announcement | DGAP News Service |
|
|
1161977 20-Jan-2021 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
